Option chain shows key data for SymBio Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for SymBio Pharmaceuticals.

SymBio Pharmaceuticals (OTC:SYMQY) Stock, Option Chain

SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in manufacturing and commercializing drugs for oncology, hematology, and pain management.

SYMBIO PHARMS LTD S/ADR by Symbio Pharmaceuticals Ltd

SymBio Pharmaceuticals Ltd

WIIM

ALDX

Aldeyra Therapeutics shares are trading higher after the FDA accepted its resubmitted new drug application for Reproxalap for the treatment of dry eye disease, prompting the company to announce an expansion of its option agreement with AbbVie.

HCWB

HCW Biologics shares are trading higher after the company entered into an exclusive licensing deal with WY Biotech for immunotherapy development.

Jones Trading analyst Catherine Novack initiates coverage on Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy rating and announces Price Target of $40.

News

Price Target

Initiation

Analyst Ratings

CAPR

Jones Trading Initiates Coverage On Capricor Therapeutics with Buy Rating, Announces Price Target of $40

NIVF

NewGenIvf shares are trading higher after the company inked a binding term sheet with White Lion Capital for a $100 million equity line of credit, expandable to $500 million.

RGNX

REGENXBIO shares are trading higher after the company announced dosing the first patient in its pivotal trial for Duchenne gene therapy.

Buybacks

Globe Life Announces $1.8B Share Repurchase Authorization; Authorization Replaces Previous $1.3B Authorization

Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.70) by 15.71 percent. This is a 27.16 percent increase over losses of $(0.81) per share from the same period last year. The company reported quarterly sales of $84.71 million which beat the analyst consensus estimate of $82.20 million by 3.05 percent. This is a 26.53 percent increase over sales of $66.95 million the same period last year.

Earnings

TWST

Twist Bioscience Q4 2024 GAAP EPS $(0.59) Beats $(0.70) Estimate, Sales $84.71M Beat $82.20M Estimate

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) with a Buy and maintains $5 price target.

Reiteration

ABUS

HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

Aldeyra Therapeutics Announces FDA Acceptance For Review Of The Resubmitted New Drug Application For Reproxalap In Treatment Of Dry Eye Disease; Based On FDA Acceptance, Co. Announces Expansion Of Option Agreement With AbbVie

Biotech

Guidance

Health Care

General

CLRB

Cellectar Biosciences' Q3 Cash And Cash Equivalents Of $34.3M Is Expected To Provide Cash Runway Into Q2 2025

Jefferies analyst Maury Raycroft initiates coverage on Erasca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERAS#NASDAQ">ERAS</a>) with a Buy rating and announces Price Target of $6.

ERAS

Jefferies Initiates Coverage On Erasca with Buy Rating, Announces Price Target of $6

HCW Biologics Inc. ("HCWB" or "HCW Biologics"), (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that they have entered into a worldwide exclusive license agreement to develop and commercialize one of HCWB's product candidates generated with its new drug discovery platform for therapeutic use.
Key terms of the agreement include that WY Biotech has agreed to pay HCWB $7.0 million in an upfront payment, and HCWB is eligible to receive additional significant development milestone payments and double-digit royalties on future product sales. In addition, HCWB will share a substantial portion of the proceeds from a future transaction(s) involving the molecule, if such a transaction occurs. HCWB also has a payment-free, milestone-free, and royalty-free option to recapture the development and commercialization rights of this molecule for the United States, Canada, Central America, and South America (Opt-in Territory) after the conclusion of the Phase 1 clinical trial. WY Biotech is financially responsible for all costs associated with research and development, manufacturing, clinical development, regulatory approval, and commercialization for the molecule. HCWB will be responsible for costs associated with clinical development, regulatory approval, and commercialization in the Opt-in Territory, if HCWB exercises its opt-in rights. Both companies will work cooperatively in the development stage with a global focus for clinical development and partnering.

HCW Biologics Enters Exclusive Licensing Deal with WY Biotech for Immunotherapy Development

Jefferies analyst Surinder Thind initiates coverage on Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy rating and announces Price Target of $28.

INGM

Jefferies Initiates Coverage On Ingram Micro Holding with Buy Rating, Announces Price Target of $28

Needham analyst James Ricchiuti maintains Bel Fuse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BELFB#NASDAQ">BELFB</a>) with a Buy and raises the price target from $79 to $95.

BELFB

Needham Maintains Buy on Bel Fuse, Raises Price Target to $95

Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical responses based on eight patients dosed across the ongoing Phase 1/2 RESET-Myositis&#x2122;, RESET-SLE&#x2122; and RESET-SSc&#x2122; clinical trials. These data were presented in oral and poster presentations at the American College of Rheumatology (ACR) Convergence 2024, which is being held at the Walter E. Washington Convention Center in Washington, D.C. from November 14-19, 2024. Presentation materials featured at ACR Convergence 2024 can be accessed on the Company's website <a href="https://www.globenewswire.com/Tracker?data=NuB6bQJy6vE4R3OJFuE3vuxsoEvSwrwTyUPI4fvYmIBT0fvL012yVTAn9S9Yo8LyN19qNwjGHz6igro953l94X3M59TLKikZQzitchedLPtNyy589YOrDdQygeY7PaRT">here</a>.
"The clinical data reported at ACR Convergence this weekend support the potential of the current dose of CABA-201 to provide immunosuppressant-free, compelling clinical responses in patients with active, refractory autoimmune disease. Data presented from the previously reported patient with lupus nephritis who experienced ICANS and had acute inflammatory events shortly before CABA-201 treatment demonstrated an abnormal, pro-inflammatory cytokine profile prior to and after CABA-201 infusion, suggestive of an occult infection. As a result of these data, subjects in the RESET clinical program who develop a fever prior to scheduled infusion will wait a minimum of two weeks before administration of CABA-201. Other than this patient with a second, later peak expansion, CABA-201 displayed a consistent PK and PD profile in all other patients," said David J. Chang, M.D., Chief Medical Officer of Cabaletta. "In addition to our promising clinical and translational data set from the RESET program, we believe our efficient clinical trial design, growing footprint of 40 actively recruiting U.S. clinical sites and anticipated expansion into Europe in 2025 provide us with a differentiated opportunity to accelerate development of CABA-201 for patients. Data permitting, we anticipate meeting with the FDA in 2025 to discuss potential registrational trial designs for CABA-201 that will allow us to bring the therapeutic potential of this investigational therapy closer to autoimmune patients."
Cabaletta designed CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, to deeply and transiently deplete CD19-positive B cells following a one-time infusion that may enable a reset of the immune system with the potential for durable remission without chronic immunosuppressive therapies in patients with autoimmune diseases. Cabaletta is currently evaluating CABA-201 in the RESET clinical development program across five company-sponsored clinical trials that each have disease-specific cohorts with six patients per cohort. All cohorts are evaluating the same single, weight-based dose of CABA-201 at 1 x 106&nbsp;cells/kg without a dose escalation requirement. Treatment with CABA-201 in each clinical trial includes a preconditioning regimen of fludarabine and cyclophosphamide, consistent with the dosing regimen used in the third-party academic studies, except for the RESET-PV&#x2122; trial which is evaluating CABA-201 without preconditioning.

CABA

Cabaletta Bio's CABA-201 Shows Results in Autoimmune Disease Trials

Fiscal 2025 Guidance:
<ul>
<li>The Company's Adjusted Diluted EPS&#x2A; guidance for the year ending July 31, 2025 remains unchanged at $4.40 to $4.70 per share, and the Company's GAAP earnings per diluted Class A Nonvoting Common Share guidance for the year ending July 31, 2025, was updated for amortization and other acquisition-related charges to $4.02 to $4.32 per share.</li>
<li>The other assumptions included in our fiscal 2025 guidance are effectively unchanged. We expect a full-year income tax rate of approximately 20 percent, depreciation and amortization expense of approximately $40 million, and capital expenditures of approximately $35 million. Our fiscal 2025 guidance is based on foreign currency exchange rates as of October 31, 2024, and assumes continued economic growth.</li>
</ul>

Brady Sees 2025 Adj EPS Guidance Of $4.40-$4.70 Vs. $4.59 Est.

Needham analyst John Todaro upgrades Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Hold to Buy and announces $40 price target.

Upgrades

HOOD

Needham Upgrades Robinhood Markets to Buy, Announces $40 Price Target

REGENXBIO Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) today announced that AFFINITY DUCHENNE&#xAE;, the multi-center, open-label trial of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy (Duchenne), has advanced to pivotal stage and dosed its first patient. The company also announced new, positive efficacy and safety data from the Phase I/II portion of the study, including the first functional data.
"The initiation of our pivotal trial and newly released positive functional data are exciting milestones on our path to rapidly deliver RGX-202, the only next generation gene therapy in pivotal phase, to the Duchenne community," said Curran M. Simpson President and Chief Executive Officer of REGENXBIO. "The totality of our data demonstrates that RGX-202 provides evidence of improving outcomes for boys with Duchenne and altering the trajectory of this devastating disease, with consistent, robust expression of our novel microdystrophin translating into significant clinical benefit. Based on the strength of the Phase I/II data and our positive discussions and alignment with the FDA, we are quickly advancing RGX-202 toward a BLA filing in 2026 using the accelerated approval pathway. We continue to evaluate opportunities to expand the RGX-202 program to benefit Duchenne patients worldwide."
"There remains a critical need for new therapeutic options for patients with Duchenne muscular dystrophy", said Aravindhan Veerapandiyan M.D., Arkansas Children's Hospital. "I am very pleased to see the advancement of the RGX-202 program to the pivotal stage, which offers promise for a broader patient population and am highly encouraged by the functional data presented today demonstrating RGX-202's potential to alter the course of the disease. The safety, functional, and biomarker data shared today reinforce the positive feedback from families, highlighting improvements in patients' daily activities and underscoring the potential benefits of this treatment."

REGENXBIO Doses First Patient in Pivotal Trial for Duchenne Gene Therapy

U.S. stocks could get off to a tentative start on Monday after investors switched to a <a href="https://www.benzinga.com/news/econ-s/24/11/42017118/stocks-tumble-as-traders-rethink-feds-action-vix-spikes-17-nasdaq-erases-back-post-trump-gains-whats-driving-markets-friday">risk-on mode last week</a> as the post-election rally lost some of its steam.
Economic data and Federal Reserve chair Jerome Powell's comments about the future of rate cuts put the sentiment on a dampener. Powell said the Federal Open Market Committee (FOMC) is not in a hurry after economic data showed strength.
Expectations of a further 25 basis point rate cut in December have fallen to just 62% now, down from 72% last week, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group's FedWatch tool.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.44%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.09%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.20%</td>
</tr>
<tr>
<td>R2K</td>
<td>0.52%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.13% to $586.50 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.45% to $498.78, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data</a>.
Cues From Last Week:
All three major indices registered a decline last week, with the tech-heavy Nasdaq seeing a bigger fall. This was the week prior, Dow Jones and S&amp;P 500 registered their best week of the year after the election of Trump as the 47th U.S. president.
On the economic data front, U.S. export prices increased by 0.8% in October, while import prices rose by 0.3% month-over-month in October. U.S. retail sales rose 0.4% month-over-month in October compared to a revised 0.8% increase in September, topping market estimates of 0.3%
Most sectors on the S&amp;P 500 closed on a negative note, with information technology, communication services, and healthcare stocks recording the biggest losses on Friday.
However, utilities and financials stocks bucked the overall market trend, closing the session higher.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Week&#8217;s Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-2.92%</td>
<td>18,680.12</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-2.28%</td>
<td>5,870.62</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-2.34%</td>
<td>43,444.99</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-5.04%</td>
<td>2,303.84</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Wells Fargo's Jay Bryson thinks the recent surge in inflation could needle the Fed to reevaluate its pace of rate cuts.
"Slower progress on inflation in recent months may prompt the Fed to reevaluate its pace of easing moving forward," he said.
On the other hand, investors will keep a close eye on earnings from AI bellwether Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), while Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) investors will be interested in President-elect Donald Trump's policy outlook on regulations for autonomous driving.
Ryan Detrick, chief market strategist at Carson Group, maintained his bullish outlook on equities.
"The S&amp;P 500 is looking at back-to-back 20% gains. The four previous times it did this (since WWII) the next year did this: 2.6%, 31%, 26.7%, 19.5%."
He underscored that while it's not unwise to be cautious about the ongoing rally, investors should not base their concerns on the upward movement so far.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 is looking at back-to-back 20% gains. The four previous times it did this (since WWII) the next year did this: +2.6% +31.0% +26.7% +19.5% Sure, there are reasons to be cautious, but stocks up a lot two years in a row shouldn&#39;t be one of them.
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1858235842851954762?ref_src=twsrc%5Etfw">November 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Nathan Peterson, Director of Derivatives Analysis at the Schwab Center for Financial Research, laid<a href="https://www.schwab.com/learn/story/weekly-traders-outlook/"> out</a> the thesis for market movements for the next week.
"I wouldn&#8217;t be surprised to see an attempt to rally from these levels at the beginning of the week if we can bounce from today&#8217;s lows into the close," Peterson said.
"Further rotation out of the largest market cap sector, Information Technology, or a negative response to Nvidia&#8217;s guidance, leading to a further downdraft in overall price action."
Peterson continues to maintain a cautious stance and noted that investors will wait for Nvidia earnings with bated breath.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
While this week's economic calendar is not as heavy as last week's, some crucial data is scheduled for the days ahead.
<ul>
<li>On Monday, the home builder confidence index is set to be released at 10 a.m. ET.</li>
<li>Chicago Fed President Austan Goolsbee&nbsp;will speak at 10 a.m. ET.</li>
<li>On Tuesday, data on new home construction and building permits will be released at 8:30 a.m. ET.</li>
<li>Chicago Fed President Austan Goolsbee&nbsp;will speak at 12:25 p.m. ET.</li>
<li>On Wednesday, Fed Gov. Lisa Cooks will speak at 11 a.m. ET.</li>
<li>Fed Gov. Michelle Bowman will speak at 12:15 p.m. ET.</li>
<li>On Thursday, initial jobless claims data will be released at 8:30 a.m. ET.</li>
<li>Philadelphia Fed manufacturing survey will be released at 8:30 a.m. ET.</li>
<li>Cleveland Fed President Beth Hammack will speak at 8:45 a.m. ET.</li>
<li>Existing home sales data and leading economic index will be released at 10 a.m. ET.</li>
<li>Kansas City Fed President Jeff Schmid will speak at 1:10 p.m. ET.</li>
<li>Fed Vice Chair for Supervision Michael Barr will speak at 4:40 p.m. ET.</li>
<li>On Friday, the S&amp;P U.S. Services and Manufacturing Purchasing Manager's Index will be released at 9:45 a.m. ET.</li>
<li>Consumer sentiment data will be released at 10 a.m. ET.</li>
<li>Fed Gov. Michelle Bowman will speak at 6:15 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will be in focus after reports of Trump's transition team looking to create a <a href="https://www.benzinga.com/pre-market-outlook/24/11/42031099/tesla-stock-responds-to-fsd-nod-in-monday-premarket-as-trump-team-prioritizes-self-driving-framework">framework for self-driving vehicles</a>. Tesla stock was up 7.9% in premarket trading on Monday.</li>
<li>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares fell over 2% in premarket trading after reports said that its Blackwell AI chips are <a href="https://www.benzinga.com/24/11/42028342/blackwell-backfires-nvidias-ai-chips-struggle-with-server-overheating-impacting-meta-microsoft-and-musks-xai-data-centers">facing overheating issues</a>.</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares were up over 12% in premarket trading after reports suggested that the company is looking to submit a plan to be in compliance once again with the listing requirements to trade on the Nasdaq.</li>
<li>Warner Bros. Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) shares surged over 1% after the company reached an agreement with the National Basketball Association (NBA) over TV rights.</li>
<li>T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) shares will also be watched closely after the company was <a href="https://www.benzinga.com/24/11/42022124/t-mobile-hit-by-chinese-hackers-after-rivals-att-verizon-suffer-breach-report">hit by Chinese hackers</a>.</li>
<li>Investors are awaiting earnings results from Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>), Brady Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>), and AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, gaining 0.78% to hover around $67.44.
The 10-year Treasury note yield continued to surge, rising to 4.465%.
Major Asian markets ended mixed on Monday, with Japan's Nikkei 225 falling the most. A similar sentiment was also visible in European markets, which demonstrated tentativeness in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42028334/bitcoin-ethereum-dogecoin-slip-as-feds-hawkish-stance-tempers-rally-analyst-expects-btc-to-reach-100k-before-new-year">Bitcoin, Ethereum, Dogecoin Slip As Fed&#8217;s Hawkish Stance Tempers Rally: Analyst Expects BTC To Reach $100K Before New Year</a></li>
</ul>
Photo courtesy: Wikimedia

Equities

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

NVDA

SMCI

TCOM

TMUS

TSLA

US Stocks On Edge As Investors Gear Up For Nvidia, Retail Earnings: Analyst Updates S&P 500 Target For 2025, Says Market Is 'Expensive'

Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) today announced that its Board of Directors (the "Board") has determined and agreed with Gregg Lowe that he will depart this month from his roles as Wolfspeed's President and Chief Executive Officer and as a member of the Board. The Board is conducting a search to identify a permanent CEO with the support of a leading global executive search firm.
The Board has appointed Thomas Werner, Chairman of the Board, as Executive Chairman while the Board works to identify Wolfspeed's next CEO. Mr. Werner will oversee the continued execution of Wolfspeed's strategy in close alignment with Wolfspeed's senior leadership team, the Board and the Board's operations and finance committees. Following Mr. Werner's appointment as Executive Chairman, Board member Stacy Smith was appointed as Lead Independent Director.
"On behalf of the full Board, I would like to thank Gregg for his service and dedication to Wolfspeed," Mr. Werner said. "Since joining the Company as CEO in 2017, Gregg has spearheaded our transition into a leading, pure-play silicon carbide company well-positioned to capture the long-term opportunities ahead. The Board has always been focused on driving long-term value, and at this inflection point in Wolfspeed's journey, the Board agreed that this is the right time for a leadership transition."
Mr. Werner added, "I have started in the role of Executive Chairman to keep Wolfspeed focused on completing key priorities while the Board conducts a search for our next CEO. I look forward to working closely with our highly engaged Board and senior leadership team to oversee day-to-day operations and ensure we continue to provide our customers with high-quality products. As we look ahead, we are firmly committed to our key strategic initiatives, which includes executing against the milestones outlined in our recent CHIPS PMT agreement, completing our restructuring initiatives to lower our break-even point and accelerate our path towards profitability, and delivering sales growth on a consistent basis. Wolfspeed is materially undervalued relative to its strategic value and I will focus on driving the Company's priorities and working with the Finance Committee of the Board to explore options to unlock value."
Mr. Lowe said, "I am honored to have had the opportunity to lead Wolfspeed and work alongside such talented and dedicated colleagues. Over the past seven years, we have transformed Wolfspeed into the only pure-play and vertically integrated silicon carbide operator in the country to capitalize on the structural and long-term demand for next generation semiconductor technology. While there is work still to be done, I have every confidence that Wolfspeed will execute on its strategic priorities and extend its silicon carbide leadership in the years to come."

Management

WOLF

Wolfspeed CEO Gregg Lowe Steps Down; Board Chairman Thomas Werner Takes Interim Leadership Role

SymBio Pharmaceuticals

Comments

SymBio Pharmaceuticals

SymBio Pharmaceuticals (SYMQY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga